MultiCell Technologies - About the company
MultiCell Technologies is a public company based in Woonsocket (United States), founded in 1970. It operates as a Developer of therapeutics for neurological disorders, hepatic disease, and cancer. MultiCell Technologies has raised an undisclosed amount in funding. The company has 3342 active competitors, including 1129 funded and 783 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of therapeutics for neurological disorders, hepatic disease, and cancer. its lead candidate, MCT-125, is an oral small-molecule drug combination that targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary Multiple Sclerosis-related fatigue. MCT-465 (liver cancer), MCT-475 (triple negative breast cancer), and MCT-485 (liver cancer) are prospective cancer therapeutics developed using MultiCell's patented therapeutic antibody and synthetic dsRNA technologies.
- Website
- multicelltech.com
- Social
- Email ID
- *****@multicelltech.com
Key Metrics
Founded Year
1970
Location
Woonsocket, United States
Stage
Public
Latest Funding Round
Ranked
1662nd among 3342 active competitors
Employee Count
10 as on Aug 31, 2026
Similar Companies
Exit Details
Public
Legal entities associated with MultiCell Technologies
MultiCell Technologies is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Multicell Technologies Inc CIN: 1363980 , United States, Active | - | - | - |
MultiCell Technologies's IPO details
MultiCell Technologies got listed on Jan 07, 2000.
Click here to take a look at MultiCell Technologies's IPO in detail
Sign up to download MultiCell Technologies' company profile
MultiCell Technologies's funding and investors
MultiCell Technologies has raised funding over 8 rounds. Its first funding round was on Jul 12, 2004. Its latest funding round was a Grant (prize money) round on Jan 03, 2012 for $*****. 1 investor participated in its latest round. MultiCell Technologies has 3 institutional investors.
Here is the list of recent funding rounds of MultiCell Technologies:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 03, 2012 | 7173824 | Grant (prize money) | 9580546 | 5118258 | 4908620 | 9000674 |
2011 | 6599 | Grant (prize money) | 2922 | 1562 | 5230 | |
Nov 02, 2010 | 2456825 | Grant (prize money) | 2565898 | 4012659 | 1144074 |
Access funding benchmarks and valuations. Sign up today!View details of MultiCell Technologies's funding rounds and investors
MultiCell Technologies' founders and board of directors
Founder? Claim ProfileMultiCell Technologies' employee count trend
MultiCell Technologies has 10 employees as of Aug 26. Here is MultiCell Technologies's employee count trend over the years:
Uncover MultiCell Technologies' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
MultiCell Technologies's Competitors and alternates
Top competitors of MultiCell Technologies include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of MultiCell Technologies, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
1662nd | MultiCell Technologies 1970, Woonsocket (United States), Public | Developer of therapeutics for neurological disorders, hepatic disease, and cancer | - | 32/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on MultiCell Technologies's competitors? Click here to see the top ones
MultiCell Technologies's Investments and acquisitions
MultiCell Technologies has made no investments or acquisitions yet.
Reports related to MultiCell Technologies
Here is the latest report on MultiCell Technologies's sector:
Are you a Founder ?
FAQs about MultiCell Technologies
Explore our recently published companies
- BIA Home Care Service - Pittsburgh based, 2021 founded, Unfunded company
- JK Auto & Truck Repair - Marlton based, Unfunded company
- Lippert - Elkhart based, 1956 founded, Unfunded company
- AMZ Tech Solutions - Cedar Rapids based, Unfunded company
- ItsGuru - Houston based, 2006 founded, Unfunded company
- Anh Totti Nguyen - Unfunded company
